Immuneering Corporation (IMRX) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 7 recommend buying, 4 recommend holding, and 0 recommend selling.
The analyst consensus price target for IMRX is $12.00, representing a +121.8% upside from the current price of $5.41. Price targets range from a low of $12.00 to a high of $12.00.
